TMO:NYE-Thermo Fisher Scientific Inc (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 572.05

Change

-0.58 (-0.10)%

Market Cap

USD 56.05B

Volume

1.41M

Analyst Target

USD 451.22
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Thermo Fisher Scientific Inc offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

N/A

USD 199.35B
IQV IQVIA Holdings Inc

N/A

USD 43.52B
A Agilent Technologies Inc

N/A

USD 40.25B
LH Laboratory Corporation of Amer..

N/A

USD 18.96B
DGX Quest Diagnostics Incorporated

N/A

USD 17.31B
CRL Charles River Laboratories

N/A

USD 10.65B
QGEN Qiagen NV

N/A

USD 9.98B
VNRX Volitionrx Ltd

N/A

USD 0.06B
ENZ Enzo Biochem Inc

N/A

USD 0.06B
MTD Mettler-Toledo International I..

N/A

N/A

ETFs Containing TMO

XDNA 9.55 % 0.00 %

N/A

N/A
SYNB Putnam Biorevolution ETF 7.69 % 0.00 %

N/A

USD 5.43M
DBPD:XETRA Xtrackers ShortDAX x2 Dai.. 6.60 % 0.00 %

N/A

USD 0.13B
LIFE-U:CA Evolve Global Healthcare .. 5.51 % 0.00 %

N/A

N/A
LIFE:CA Evolve Global Healthcare .. 5.24 % 0.69 %

N/A

CAD 0.22B
FHI:CA CI Health Care Giants Cov.. 5.02 % 0.75 %

N/A

CAD 0.07B
THNR Amplify ETF Trust 4.91 % 0.00 %

N/A

N/A
BGU:CA Bristol Gate Concentrated.. 4.75 % 0.85 %

N/A

CAD 0.12B
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.55 % 0.00 %

N/A

USD 0.15B
DXSI:XETRA Xtrackers - Stoxx Europe .. 4.55 % 0.00 %

N/A

USD 0.02B
AILG 4.51 % 0.00 %

N/A

N/A
XSDX:SW Xtrackers ShortDAX Daily .. 4.48 % 0.00 %

N/A

USD 0.20B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.34 % 0.00 %

N/A

N/A
MHCD:CA Middlefield Healthcare Di.. 4.19 % 0.00 %

N/A

CAD 0.16B
XLV Health Care Select Sector.. 4.13 % 0.13 %

N/A

USD 42.10B
QDVG:XETRA iShares S&P 500 Health Ca.. 4.11 % 0.00 %

N/A

USD 2.05B
XGES:LSE Xtrackers MSCI Genomic He.. 4.10 % 0.00 %

N/A

N/A
SXLV:SW SPDR S&P U.S. Health Care.. 4.06 % 0.00 %

N/A

N/A
ZPDH:F SPDR S&P U.S. Health Care.. 4.05 % 0.00 %

N/A

USD 0.40B
IUHC:SW iShares S&P 500 Health Ca.. 3.92 % 0.00 %

N/A

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.92 % 0.00 %

N/A

N/A
XUHC:F Xtrackers (IE) Public Lim.. 3.91 % 0.00 %

N/A

USD 0.85B
XUHC:SW Xtrackers MSCI USA Health.. 3.91 % 0.00 %

N/A

USD 0.69B
WH2E:XETRA Invesco Markets II plc - .. 3.83 % 0.00 %

N/A

USD 0.08B
CFCV 3.60 % 0.00 %

N/A

N/A
PINK Simplify Exchange Traded .. 3.57 % 0.00 %

N/A

USD 0.25B
FHLC Fidelity® MSCI Health Ca.. 3.54 % 0.08 %

N/A

USD 3.01B
DRUG:AU BetaShares Global Healthc.. 3.43 % 0.00 %

N/A

USD 0.17B
FOHW:XETRA Franklin Future of Health.. 3.02 % 0.00 %

N/A

USD 2.81M
XWHS:LSE Xtrackers MSCI World Heal.. 2.91 % 0.00 %

N/A

USD 2.99B
WHEA:SW SPDR MSCI World Health Ca.. 2.91 % 0.00 %

N/A

N/A
XDWH:F Xtrackers (IE) Public Lim.. 2.77 % 0.00 %

N/A

USD 2.60B
HEAW:LSE SPDR® MSCI World Health .. 2.71 % 0.00 %

N/A

N/A
ABIT:F AXA IM ACT Biodiversity E.. 2.63 % 0.00 %

N/A

N/A
ABIE:F AXA IM ACT Biodiversity E.. 2.63 % 0.00 %

N/A

N/A
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.62 % 0.00 %

N/A

N/A
GMVM:XETRA VanEck Morningstar US Sus.. 2.55 % 0.00 %

N/A

USD 0.53B
MOAT:SW VanEck Morningstar US Sus.. 2.55 % 0.00 %

N/A

N/A
CDNA:CA 2.53 % 0.00 %

N/A

N/A
MOGB:LSE VanEck Morningstar US Sus.. 2.51 % 0.00 %

N/A

USD 0.48B
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.44 % 0.00 %

N/A

N/A
LRGE ClearBridge Large Cap Gro.. 2.35 % 0.59 %

N/A

USD 0.38B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.20 % 0.00 %

N/A

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.20 % 0.00 %

N/A

N/A
HYLG Global X Funds - Global X.. 1.84 % 0.00 %

N/A

N/A
PSET Principal Quality ETF 1.56 % 0.29 %

N/A

USD 0.06B
DFUV Dimensional US Marketwide.. 1.24 % 0.00 %

N/A

USD 11.10B
VONV Vanguard Russell 1000 Val.. 0.94 % 0.12 %

N/A

USD 9.38B
GVUS Goldman Sachs ETF Trust 0.94 % 0.00 %

N/A

USD 0.39B
JPST JPMorgan Ultra-Short Inco.. 0.74 % 0.00 %

N/A

USD 25.59B
CURE Direxion Daily Healthcare.. 0.00 % 1.06 %

N/A

USD 0.20B
IBLN 0.00 % 0.64 %

N/A

N/A
IWX iShares Russell Top 200 V.. 0.00 % 0.20 %

N/A

USD 3.13B
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

N/A

N/A
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
LDUR PIMCO Enhanced Low Durati.. 0.00 % 1.02 %

N/A

USD 0.86B
JMIN 0.00 % 0.12 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

N/A

USD 5.65B
KORP American Century Diversif.. 0.00 % 0.45 %

N/A

USD 0.31B
LS:CA 0.00 % 2.21 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
CGAA:CA CI Global Asset Allocatio.. 0.00 % 0.00 %

N/A

CAD 0.03B
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.00 %

N/A

CAD 0.05B
VRVIX Vanguard Russell 1000 Val.. 0.00 % 0.00 %

N/A

USD 9.85B
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

N/A
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

N/A

CAD 0.66B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
IUHC:LSE iShares S&P 500 USD Healt.. 0.00 % 0.00 %

N/A

USD 2.54B
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

N/A
WHEA:LSE SPDR® MSCI World Health .. 0.00 % 0.00 %

N/A

N/A
XDWH:LSE Xtrackers MSCI World Heal.. 0.00 % 0.00 %

N/A

N/A
XFVT:LSE Xtrackers FTSE Vietnam Sw.. 0.00 % 0.00 %

N/A

N/A
XSD2:LSE db x-trackers ShortDAX x2.. 0.00 % 0.00 %

N/A

USD 0.14B
XSHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.68B
XUHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.68B
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
XAIN:XETRA Xtrackers - MSCI Indonesi.. 0.00 % 0.00 %

N/A

USD 0.05B
XDWH:XETRA Xtrackers MSCI World Heal.. 0.00 % 0.00 %

N/A

USD 2.60B
XUHC:XETRA Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.85B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

USD 0.40B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
IXJ:AU iShares Global Healthcare.. 0.00 % 0.00 %

N/A

USD 1.47B
DWEQ 0.00 % 0.00 %

N/A

N/A
BGU-U:CA Bristol Gate Concentrated.. 0.00 % 0.00 %

N/A

CAD 0.11B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

N/A

CAD 0.09B
PFUT Putnam Sustainable Future.. 0.00 % 0.00 %

N/A

USD 0.27B
SROI Calamos Antetokounmpo Glo.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.77% 85% B 73% C
Dividend Return 0.15% 43% F 5% F
Total Return 7.92% 85% B 70% C-
Trailing 12 Months  
Capital Gain 6.47% 77% C+ 57% F
Dividend Return 0.15% 17% F 2% F
Total Return 6.61% 77% C+ 46% F
Trailing 5 Years  
Capital Gain 100.54% 100% F 86% B+
Dividend Return 1.75% 20% F 5% F
Total Return 102.28% 100% F 85% B
Average Annual (5 Year Horizon)  
Capital Gain 17.09% 85% B 82% B
Dividend Return 17.31% 77% C+ 80% B-
Total Return 0.22% 17% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 23.25% 69% C- 46% F
Risk Adjusted Return 74.44% 100% F 98% N/A
Market Capitalization 56.05B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.96 50% 17%
Price/Book Ratio 4.62 46% 19%
Price / Cash Flow Ratio 26.15 38% 11%
Price/Free Cash Flow Ratio 21.90 31% 12%
Management Effectiveness  
Return on Equity 13.62% 62% 69%
Return on Invested Capital 8.92% 54% 61%
Return on Assets 4.82% 54% 71%
Debt to Equity Ratio 67.01% 38% 49%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.